FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesPelican webinar - Impact of COVID-19 on Cold Chain
Topics: Cold Chain, Supply Chain
Webinar
Free
Video on ACE Requirements
Topics: Pharma Industry, Strategic Planning
Video
Members
Lessons Learned: Conducting COVID Clinical Trials and Building a Clinical Supplies Team During the Peak of the Pandemic
Topics: Conference, COVID-19
Executive Summary
Members
